StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Puma Biotechnology ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Puma Biotechnology's ebitda for the twelve months ending Jun 30, 2026 was $40.92M, down 28.6% year over year. For fiscal 2025 it was $48.24M, up 13.5% from the year before. The highest annual figure on record is $48.24M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$48.24M+13.5%
FY2024Dec 31, 2024$42.49M-3.8%
FY2023Dec 31, 2023$44.16M+31.6%
FY2022Dec 31, 2022$33.56M+166.5%
FY2021Dec 31, 2021$12.60M–
FY2020Dec 31, 2020-$20.37M–
FY2019Dec 31, 2019-$30.97M–
FY2018Dec 31, 2018-$87.27M–
FY2017Dec 31, 2017-$289.58M–
FY2016Dec 31, 2016-$275.45M–
FY2015Dec 31, 2015-$239.50M–
FY2014Dec 31, 2014-$141.65M–
FY2013Dec 31, 2013-$54.41M–
FY2012Dec 31, 2012-$74.19M–
FY2011Dec 31, 2011-$10.15M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$10.10M+7.5%
Q1 FY2026Mar 31, 2026-$1.24M-118.3%
Q4 FY2025Dec 31, 2025$19.76M+21.9%
Q3 FY2025Sep 30, 2025$12.30M-50.7%
Q2 FY2025Jun 30, 2025$9.40M+1189.3%
Q1 FY2025Mar 31, 2025$6.78M+1033.8%
Q4 FY2024Dec 31, 2024$16.21M-8.4%
Q3 FY2024Sep 30, 2024$24.96M+117.8%
Q2 FY2024Jun 30, 2024$729.00K-90.6%
Q1 FY2024Mar 31, 2024$598.00K-91.7%
Q4 FY2023Dec 31, 2023$17.69M+41.8%
Q3 FY2023Sep 30, 2023$11.46M+135.7%
Q2 FY2023Jun 30, 2023$7.77M-46.5%
Q1 FY2023Mar 31, 2023$7.24M+323.6%
Q4 FY2022Dec 31, 2022$12.47M+27.1%
Q3 FY2022Sep 30, 2022$4.86M–
Q2 FY2022Jun 30, 2022$14.52M–
Q1 FY2022Mar 31, 2022$1.71M-92.6%
Q4 FY2021Dec 31, 2021$9.81M–
Q3 FY2021Sep 30, 2021-$6.51M–
Q2 FY2021Jun 30, 2021-$13.70M-246.3%
Q1 FY2021Mar 31, 2021$23.10M–
Q4 FY2020Dec 31, 2020-$8.20M–
Q3 FY2020Sep 30, 2020-$9.20M–
Q2 FY2020Jun 30, 2020$9.37M–
Q1 FY2020Mar 31, 2020-$12.34M-202.9%
Q4 FY2019Dec 31, 2019-$6.77M–
Q3 FY2019Sep 30, 2019-$12.51M–
Q2 FY2019Jun 30, 2019-$23.68M–
Q1 FY2019Mar 31, 2019$11.98M–
Q4 FY2018Dec 31, 2018-$16.43M–
Q3 FY2018Sep 30, 2018-$9.23M–
Q2 FY2018Jun 30, 2018-$39.56M–
Q1 FY2018Mar 31, 2018-$22.05M–
Q4 FY2017Dec 31, 2017-$62.21M–
Q3 FY2017Sep 30, 2017-$76.54M–
Q2 FY2017Jun 30, 2017-$77.91M–
Q1 FY2017Mar 31, 2017-$72.93M–
Q4 FY2016Dec 31, 2016-$72.29M–
Q3 FY2016Sep 30, 2016-$65.89M–

More Puma Biotechnology figures

See a number that looks wrong?